UB Paderborn / Katalog / Suche / in CDI

A Pharmacokinetics–Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B

Clinical pharmacology and therapeutics, 2022-08, Vol.112 (2), p.372-381

2022

Link zum Volltext

Verfügbarkeit prüfen

How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti–Hepatitis B Virus Drug

Clinical pharmacology and therapeutics, 2021-04, Vol.109 (4), p.1081-1091

2021

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer

Cancer chemotherapy and pharmacology, 2014-04, Vol.73 (4), p.737-747

2014

Link zum Volltext

Verfügbarkeit prüfen

What drives the dynamics of HBV RNA during treatment?

Journal of viral hepatitis, 2021-02, Vol.28 (2), p.383-392

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals

Clinical and translational science, 2022-05, Vol.15 (5), p.1196-1203

2022

Link zum Volltext

Verfügbarkeit prüfen

A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment

Journal of clinical pharmacology, 2013-06, Vol.53 (6), p.589-600

2013

Link zum Volltext

Verfügbarkeit prüfen

An apparent clinical pharmacokinetic drug–drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.661-671

2017

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic and Exposure–dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients

Clinical and translational science, 2018-09, Vol.11 (5), p.523-531

2018

Link zum Volltext

Verfügbarkeit prüfen

1536. Population Pharmacokinetic Analysis of Baloxavir Morboxil, a Cap-Dependent Endonuclease Inhibitor, in Adult and Adolescent Healthy Subjects and Influenza Patients and Exposure-Response Relationships in the Patients at High-Risk of Influenza Complications

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S559-S560

2019

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetic/Pharmacodynamic Modelling from the Phase I/II COMPOSER Trial to Predict Lowering of Lactate Dehydrogenase in Crovalimab-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria

Blood, 2020-11, Vol.136 (Supplement 1), p.9-10

2020

Link zum Volltext

Verfügbarkeit prüfen

Mixed effect modeling of sumatriptan pharmacokinetics during drug development : II. From healthy subjects to phase 2 dose ranging in patients

Journal of pharmacokinetics and biopharmaceutics, 1999-04, Vol.27 (2), p.149-171

1999

Link zum Volltext

Verfügbarkeit prüfen

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

The New England journal of medicine, 2022-08, Vol.387 (5), p.421-432

2022

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications

Antimicrobial agents and chemotherapy, 2020-06, Vol.64 (7)

2020

Link zum Volltext

Verfügbarkeit prüfen

Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling

Journal of pharmacokinetics and biopharmaceutics, 1997-04, Vol.25 (2), p.149-167

1997

Link zum Volltext

Verfügbarkeit prüfen

Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial

The lancet. Gastroenterology & hepatology, 2021-09, Vol.6 (9), p.723-732

2021

Link zum Volltext

Verfügbarkeit prüfen

A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration

Translational vision science & technology, 2021-05, Vol.10 (6), p.11-11

2021

Link zum Volltext

Verfügbarkeit prüfen

Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression

Frontiers in neuroscience, 2021-12, Vol.15, p.765765-765765

2021

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Patients Infected with Influenza at High Risk of Influenza Complications

Antimicrobial agents and chemotherapy, 2020-04

2020

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients

European journal of clinical pharmacology, 2004-01, Vol.59 (11), p.783-790

2004

Link zum Volltext

Verfügbarkeit prüfen

Methods to detect non-compliance and reduce its impact on population PK parameter estimates

Journal of pharmacokinetics and pharmacodynamics, 2014-06, Vol.41 (3), p.279-289

2014

Link zum Volltext

Verfügbarkeit prüfen

The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy

Neurology and therapy, 2024-02, Vol.13 (1), p.183-219

2024

Link zum Volltext

Verfügbarkeit prüfen

Imaging the norepinephrine transporter in humans with ( S , S )-[11 C] O -methyl reboxetine and PET: problems and progress

Nuclear medicine and biology, 2007-08, Vol.34 (6), p.667-679

2007

Link zum Volltext

Verfügbarkeit prüfen

Modeling of Metabolite Pharmacokinetics in a Large Pharmacokinetic Data Set: An Application

Pharmacometrics, 2007, p.1107-1136

2007

Link zum Volltext

Verfügbarkeit prüfen

Population Models for Drug Absorption and Enterohepatic Recycling

Pharmacometrics, 2007, p.345-382

2007

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

A Pharmacokinetics–Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B

How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti–Hepatitis B Virus Drug

Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer

What drives the dynamics of HBV RNA during treatment?

Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals

A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment

An apparent clinical pharmacokinetic drug–drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism

Population Pharmacokinetic and Exposure–dizziness Modeling for a Metabotropic Glutamate Receptor Subtype 5 Negative Allosteric Modulator in Major Depressive Disorder Patients

1536. Population Pharmacokinetic Analysis of Baloxavir Morboxil, a Cap-Dependent Endonuclease Inhibitor, in Adult and Adolescent Healthy Subjects and Influenza Patients and Exposure-Response Relationships in the Patients at High-Risk of Influenza Complications

Population Pharmacokinetic/Pharmacodynamic Modelling from the Phase I/II COMPOSER Trial to Predict Lowering of Lactate Dehydrogenase in Crovalimab-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria

Mixed effect modeling of sumatriptan pharmacokinetics during drug development : II. From healthy subjects to phase 2 dose ranging in patients

Trial of Prasinezumab in Early-Stage Parkinson’s Disease

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications

Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling

Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial

A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data

Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson's Disease Motor Progression

Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Patients Infected with Influenza at High Risk of Influenza Complications

Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients

Methods to detect non-compliance and reduce its impact on population PK parameter estimates

The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular Dystrophy

Imaging the norepinephrine transporter in humans with ( S , S )-[11 C] O -methyl reboxetine and PET: problems and progress

Modeling of Metabolite Pharmacokinetics in a Large Pharmacokinetic Data Set: An Application

Population Models for Drug Absorption and Enterohepatic Recycling

Suchergebnisse filtern